Hormel Foods (HRL)
Consumo básico / Alimentos envasados
Branded food company with over 30 brands (SPAM, Skippy, Planters, Jennie-O) and 389 consecutive quarters of dividend paid, whose earnings of the last twelve months are depressed by intangible impairments and the sale of the whole turkey business, while 2026 guidance and six consecutive quarters of organic growth point to margin recovery not yet reflected in market price.
- Price
- $23.69
- Intrinsic value (5y, base)
- $30
- Total annual return (5y)
- 9.4%
- Status (nominal)
- Fairly valued
- Margin of safety
- +19%
The essentials
- Sixth consecutive quarter of organic revenue growth, led by Foodservice (eleven consecutive quarters of organic expansion)
- Trailing twelve-month earnings are depressed by US$235 million of non-cash intangible impairments and a US$61 million loss on the sale of the whole turkey business
- Member of the S&P 500 Dividend Aristocrats with 389 consecutive quarters of dividend paid and conservative leverage
Intrinsic value — two valuation methods
Total return at 5 years: 9.6%/year = 4.8% appreciation + 4.8% dividend. The target price ($30) is ex-dividend; the $6 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $32 · Multiples $30) exceeds the market price ($24).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $24 trades ~19.8% below its value discounted to today (~$30); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($30) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$19.
Thesis
The business
Mature branded food company, capital intensive, with moderate moat (brand + distribution) under pressure from commodities and substitution by private label. Cash generation remained positive despite the decline in reported earnings, funding the dividend entirely.
The valuation
Valued by P/E on normalized net income (ex intangible impairments and loss on sale of whole turkey business), with an exit multiple within the band of a mature staple company. Value at 5 years yields +10% versus market price, Fairly valued.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. Current price reflects a high market P/E calculated on trailing twelve-month earnings distorted by non-recurring charges, not a genuine quality premium—normalized earnings suggest a fairer entry point than the reported multiple.
What to monitor
The key disconfirmer is whether consolidated volume stabilizes in the coming quarters: if private label substitution and the impact of GLP-1 medications on processed protein demand deepen, the margin recovery guided for 2026 does not materialize and the normalized recovery thesis is invalidated.
Educational / informational. Does not constitute investment advice.